Amplified Synthetic Biotechnology
Applying Cas-CLOVER and piggyBac gene editing technology to microbial gene engineering creates vast opportunities in metabolic engineering and protein production.
Efficiently Develop High-Performing Microbial Strains
Due to their exceptional natural characteristics, yeasts and other microbes play an important role as the platform for bioproduction of biofuels, therapeutics, food ingredients, and proteins.
By applying Cas-CLOVER and piggyBac gene editing technology to microbial strain engineering, these traits can be further leveraged for commercial manufacturing, product discovery, and development.
Cas-CLOVER More Precise Than CRISPR/Cas9
A clean alternative to CRISPR/Cas9, Cas-CLOVER has the potential to revolutionize synthetic biotechnology.
It utilizes a dimeric Clo051 nucleus domain recruited by guide RNAs (gRNAs). The pair of gRNAs and dimeric architecture significantly remove the risk of off-targets compared to Cas9 and other gene editing technologies.
Cas-CLOVER Validated In Yeast for High-Fidelity Targeting
Cas-CLOVER demonstrates its ability to engineer metabolic pathways for improved biochemical synthesis by making precise changes in targeted genetic material.
In this example, Cas-CLOVER editing efficiencies in this assay are comparable to CRISPR/Cas9. Both enzymes were used to disrupt a metabolic pathway in yeast, resulting in the accumulation of red pigment in vacuoles
PiggyBac Transposase Proven for Gene Integration & Stable Expression
Known for high efficiency and stable, high expression; piggyBac has demonstrated activity in a diversity of yeast strains, including many non-model organisms for commercial applications - per published data.
Small to very large stable gene integration (200KB+) enables whole pathway metabolic engineering and high expression of proteins. In this example, we integrated the Mevalonate Pathway (approximate 30 kb) with piggyBac and saw an almost 9-fold increase in β-Farnesene production with no optimization of growth conditions.
See How Scientists Are Using Our Gene Editing Tools
Hear synthetic biotechnology and gene editing thought leaders George Church, Ph.D. and Eric Ostertag, M.D., Ph.D. discuss how genetic engineering has revolutionized life science research and product development as well as insights into CRISPR/Cas9 alternatives.
George Church, Ph.D
Professor
Harvard University
Eric Ostertag, M.D., Ph.D
CEO
Poseida Therapeutics
Optimizing Your Synthetic Biotech Research?
Contact us to learn more about our innovative gene editing technology.